Cross Cancer Institute ( Site 2804)

Edmonton, Alberta T6G 1Z2

1 studies enrolling now · 1 studies all time

What they study most

Hematologic Malignancies, Solid Tumors

Studies at this site

• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) — Recruiting now